Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma
European Journal of Cancer2019Vol. 110, pp. 62–70
Citations Over TimeTop 10% of 2019 papers
Wim van Boxtel, Laura D. Locati, Adriana C. H. van Engen–van Grunsven, Cristiana Bergamini, Marianne A. Jonker, E. Fiets, Stefano Cavalieri, S. Tooten, Ewout J. van den Bos, Pasquale Quattrone, Gerald W. Verhaegh, Jack A. Schalken, Lisa Licitra, Carla M.L. van Herpen
Related Papers
- → The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamide(2005)28 cited
- → Abstract 3930: Ligand-independent activity of the mutant LNCaP androgen receptor drives cell proliferation in hormone-independent LNCaP tumor cells(2012)1 cited
- → Chemical Complementation of Androgen Receptor Mutations Associated with Androgen Independent Prostate Cancer(2007)
- → Abstract 1321: Castration-resistant prostate cancer: BAY 1024767 blocks function of mutated androgen receptor.(2013)
- → SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).(2014)